Anti-PD-L1

PD-L1 inhibitor

Drug timelines are a Plus or Pro feature.

3 regulatory and trial events tracked for Anti-PD-L1, covering 2020-11-12 to 2026-04-15. Get the full timeline:

Most recent: Clinical Trial Update: Study of Tarlatamab + ZL-1310 +/- Anti-programmed Death Ligand 1 (Anti-PD-L1) in Small Cell Lung Cancer (SCLC) [Phase 1]

See pricing